Clinical Trial: Qurse Revand for MASLD: A Randomized Controlled Safety and Efficacy Trial

U.S., Oct. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07902219) titled 'Qurse Revand for MASLD: A Randomized Controlled Safety and Efficacy Trial' on Oct. 08.

Brief Summary: This study is a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the safety, efficacy of the Unani compound formulation Qurse Revand compared to a placebo in adult participants with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

Study Start Date: May 01, 2027

Study Type: INTERVENTIONAL

Condition: MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)

Intervention: DRUG: Qurse Revand

Qurse Revand (3 tablets of 835 mg each) twice daily before meals for 60 days

DRUG: ...